# Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

> **NCT01947998** · — · COMPLETED · sponsor: **Bayer** · enrollment: 50299 (actual)

## Conditions studied

- Venous Thrombosis
- Pulmonary Embolism
- Atrial Fibrillation
- Acute Coronary Syndrome

## Interventions

- **DRUG:** Rivaroxaban (Xarelto, Bay59-7939)
- **DRUG:** Warfarin
- **DRUG:** Antiplatelet drugs

## Key facts

- **NCT ID:** NCT01947998
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12-22
- **Primary completion:** 2020-09-30
- **Final completion:** 2020-09-30
- **Target enrollment:** 50299 (ACTUAL)
- **Last updated:** 2021-09-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01947998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01947998, "Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT01947998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*